What is Phosphorex?
Phosphorex operates as a specialized Contract Development and Manufacturing Organization (CDMO) with a deep-rooted expertise in particle-based drug delivery systems. With a legacy spanning over two decades, the firm provides critical infrastructure for pharmaceutical and biotechnology entities, focusing on the complex formulation and cGMP manufacturing of lipid and polymeric nanoparticles. Their service suite encompasses the entire lifecycle of drug development, from initial formulation feasibility and process optimization to clinical-grade production. By focusing on targeted and sustained release mechanisms, Phosphorex enables its clients to enhance the safety profiles and therapeutic efficacy of their drug candidates, effectively bridging the gap between laboratory innovation and clinical application.
How much funding has Phosphorex raised?
Phosphorex has raised a total of $470K across 2 funding rounds:
Debt
$150K
Debt
$320K
Debt (2020): $150K with participation from PPP
Debt (2021): $320K led by PPP
Key Investors in Phosphorex
PPP
Public-Private Partnership
What's next for Phosphorex?
With this late-stage funding secured, Phosphorex is poised to scale its manufacturing infrastructure to meet the rising demand for sophisticated drug delivery platforms. The strategic allocation of these funds will likely prioritize the expansion of cGMP facilities and the enhancement of proprietary nanoparticle technologies. As the pharmaceutical industry continues to pivot toward precision medicine and complex biologics, Phosphorex is strategically aligned to capture increased market share. The company's focus on reliability and collaborative development will remain central to its growth strategy, ensuring that it remains a preferred partner for firms navigating the rigorous requirements of clinical trials and commercial-scale production.
See full Phosphorex company page
